Breaking News Instant updates and real-time market news.

ACHN

Achillion

$4.01

0.04 (1.01%)

, TPIC

TPI Composites

$19.09

-0.14 (-0.73%)

18:04
08/08/17
08/08
18:04
08/08/17
18:04

On The Fly: After Hours Movers

UP AFTER EARNINGS: Achillion (ACHN), up 30.9%... TPI Composites (TPIC), up 15.2%... ACADIA (ACAD), up 11.5%... Alarm.com (ALRM), up 9%... Rex Energy (REXX), up 7.7%... Gulfport Energy (GPOR), up 7.4%... Pixelworks (PXLW), up 5.1%... Hertz (HTZ), up 3.2%... GoDaddy (GDDY), up 0.7%. DOWN AFTER EARNINGS: Fossil Group (FOSL), down 20.6%... TrueCar (TRUE), down 11.1%... Maxlinear (MXL), down 10.9%... TripAdvisor (TRIP), down 7.2%... Priceline (PCLN), down 6.8%... Zillow (ZG), down 6.8%... Ocular Therapeutix (OCUL), down 6.7%... Jazz Pharmaceuticals (JAZZ), down 5.3%... Disney (DIS), down 4%... Monster Beverage (MNST), down 3.1%... Nuance Communications (NUAN), down 3.1%. ALSO LOWER: Netflix (NFLX), down 2.7% after Disney announced it would end its Netflix distribution agreement in 2019.

ACHN

Achillion

$4.01

0.04 (1.01%)

TPIC

TPI Composites

$19.09

-0.14 (-0.73%)

ACAD

Acadia

$29.54

-1.03 (-3.37%)

ALRM

Alarm.com

$39.51

0.29 (0.74%)

REXX

Rex Energy

$2.74

-0.03 (-1.08%)

GPOR

Gulfport Energy

$11.00

-0.23 (-2.05%)

PXLW

Pixelworks

$4.72

-0.14 (-2.88%)

HTZ

Hertz

$14.28

-0.96 (-6.30%)

GDDY

GoDaddy

$42.45

-0.23 (-0.54%)

FOSL

Fossil

$11.84

0.64 (5.71%)

TRUE

TrueCar

$19.51

-0.17 (-0.86%)

MXL

MaxLinear

$24.69

0.01 (0.04%)

TRIP

TripAdvisor

$39.55

-0.01 (-0.03%)

PCLN

Ticker changed to BKNG

$2,049.00

6.36 (0.31%)

Z

Zillow

$47.93

0.43 (0.91%)

ZG

Zillow

$47.74

0.31 (0.65%)

OCUL

Ocular Therapeutix

$5.95

-0.09 (-1.49%)

JAZZ

Jazz Pharmaceuticals

$152.29

-3.27 (-2.10%)

DIS

Disney

$106.98

0.63 (0.59%)

MNST

Monster Beverage

$52.63

-0.24 (-0.45%)

NUAN

Nuance

$17.02

0.02 (0.12%)

NFLX

Netflix

$178.36

-2.97 (-1.64%)

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 10

    Aug

  • 16

    Aug

  • 16

    Aug

  • 17

    Aug

  • 18

    Aug

  • 18

    Aug

  • 05

    Sep

  • 26

    Sep

  • 28

    Sep

  • 14

    Nov

ACHN Achillion
$4.01

0.04 (1.01%)

04/25/17
MAXM
04/25/17
NO CHANGE
Target $5
MAXM
Buy
Achillion price target lowered to $5 from $8 at Maxim
Maxim analyst Jason Kolbert said phase 2 trial results demonstrated that Achillion's (ACHN) triple combination of simeprevir, odalasvir and AL-335 has the ability to shorten treatment duration, be generally well tolerated and offer high efficacy for hepatitis C virus genotype 1 patients. While Johnson & Johnson (JNJ) is likely to move forward with this regimen, allowing Achillion to realize milestones, Kolbert has removed any royalties from his model as he expects others to dominate the landscape with "near perfect" regimens. Kolbert lowered his price target on Achillion to $5 from $8 but keeps a Buy rating on the shares.
05/18/17
LEER
05/18/17
UPGRADE
Target $6
LEER
Outperform
Achillion upgraded to Outperform from Market Perform at Leerink
Leerink analyst Joseph Schwartz upgraded Achillion Pharmaceuticals (ACHN) and raised his price target for the shares to $6 from $4. The analyst sees limited downside from current share levels even if the complement study fails, assuming the hepatitis C virus partnership with Johnson & Johnson (JNJ) remains intact. Schwartz assigned a "conservative" 33% probability of success to Achillion's complement program due to the lack of precedent for an oral small molecule inhibitor of complement factor D that is selective enough to avoid off target effects. He believes risks to successful ACH-4471 development are fully discounted in Achillion's current stock price.
04/24/17
BARD
04/24/17
NO CHANGE
Target $5
BARD
Outperform
Achillion price target lowered to $5 from $10 at Baird
Baird analyst Brian Skorney lowered his price target on Achillion (ACHN) to $5 from $10 on its disappointing Hep-C results, which indicated a weakness when it comes to genotype 3 patients. Although he expects partner Johnson & Johnson (JNJ) to push the trial into Phase 3, he think it makes the regimen a more difficult sell with other drugs offering genotype 3 efficacy. Skorney maintained his Outperform rating on Achillion shares.
04/25/17
JMPS
04/25/17
NO CHANGE
JMPS
Johsnson &Johnson data positive for Achillion, says JMP Securities
JMP Securities analyst Liisa Bayko says that data on a triple combination HCV treatment presented by Johnson & Johnson (JNJ) yesterday is positive for Achillion (ACHN). The analyst noted that the triple combination includes Achillion's odalasvir and that the six week treatment regimen is shorter than the eight weeks required for Gilead's (GILD) Harvoni. The analyst says that Achillion's stock dropped sharply yesterday because there was disappointment over the combination's efficacy in genotype 3 patients. However, she says that such patients only represent 10% of the total, and she says that Achillion can "conservatively" obtain peak royalty revenue of about $100M from its drug. Bayko keeps a $13 price target and an Outperform rating on the shares.
TPIC TPI Composites
$19.09

-0.14 (-0.73%)

08/16/16
08/16/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. IBM (IBM) initiated with a Perform at Oppenheimer. 2. GrubHub (GRUB) initiated with a Hold at Jefferies. 3. Broadwind Energy (BWEN) initiated with an Outperform at Cowen. 4. TPI Composites (TPIC) initiated with an Overweight at JPMorgan, with an Outperform at Cowen, with a Buy at Canaccord, with an Overweight at Morgan Stanley, and with an Outperform at Raymond James. 5. Tableau (DATA) initiated with an Outperform at Oppenheimer. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/17/17
01/17/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Kratos Defense (KTOS) initiated with a Buy at Canaccord. 2. Buckeye Partners (BPL) coverage resumed with an Equal Weight at Barclays. 3. Clovis (CLVS) and TESARO (TSRO) were initiated with an Overweight at Morgan Stanley. 4. TPI Composites (TPIC) initiated with a Buy at Roth Capital. 5. International Seaways (INSW) initiated with a Buy at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/17/17
ROTH
01/17/17
INITIATION
Target $23
ROTH
Buy
TPI Composites initiated with a Buy at Roth Capital
Roth Capital analyst Philip Shen started TPI Composites with a Buy rating and $23 price target as he sees the company as a leading global manufacturer of blades for wind turbine OEMs, and notes that it has secured long-term contracts with four of the largest turbine OEMs with contracted revenue potential of up to $4.2B through 2023.
03/31/17
LEHM
03/31/17
INITIATION
Target $24
LEHM
Overweight
TPI Composites initiated with an Overweight at Barclays
Barclays analyst Jon Windham started TPI Composites with an Overweight rating and $24 price target. The growing market opportunity for outsourced wind blades should drive continued revenue growth, the analyst argues.
ACAD Acadia
$29.54

-1.03 (-3.37%)

04/27/17
LEER
04/27/17
NO CHANGE
Target $50
LEER
Outperform
ACADIA price target lowered to $50 from $55 at Leerink
Leerink analyst Ana Gupte lowered her price target for ACADIA to $50 from $55 due to possible pricing pressures and potential delay in Priory deployment. The analyst reiterates an Outperform rating on the shares.
03/01/17
LEER
03/01/17
NO CHANGE
Target $36
LEER
Market Perform
ACADIA price target raised to $36 from $31 at Leerink
Leerink analyst Paul Matteis raised his price target for ACADIA to $36 from $31 to reflect quarterly updates and solid sales growth, and greater weight to his revenue multiple analysis. The analyst reiterates a Market Perform rating on the shares.
12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Piper lays out top BioPharma picks for 2017
Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and potentially repatriation should lead to increased merger activity.
12/20/16
LEER
12/20/16
NO CHANGE
LEER
Market Perform
ACADIA data a 'clear upside' but benefit looks modest, says Leerink
Leerink analyst Paul Matteis notes that ACADIA has announced positive top-line data from its Phase 2 study of pimavanserin in Alzheimer's Disease Psychosis. While the analyst believes the benefit looks "modest," he says the announcement represents "clear upside to expectations," which were low into the event. Leerink has a Market Perform on the shares.
ALRM Alarm.com
$39.51

0.29 (0.74%)

05/11/17
MAXM
05/11/17
INITIATION
Target $19
MAXM
Hold
Control4 initiated with a Hold at Maxim
Maxim analyst Nehal Chokshi initiated Control4 (CTRL) with a Hold rating and $19 price target. His proprietary dealer checks indicate Control4 should continue to gain share in the professionally installed "entertainment first" smart home market, but he thinks its significant discount to smart home peer Alarm.com (ALRM) is warranted given its smaller addressable market, lower growth and worse earnings visibility.
03/17/17
IMPC
03/17/17
UPGRADE
Target $35
IMPC
Outperform
Alarm.com upgraded to Outperform from In-Line at Imperial Capital
Imperial Capital analyst Jeff Kessler upgraded Alarm.com to Outperform following the company's Q4 results and raised his price target for the shares to $35 from $30.
06/09/17
NORL
06/09/17
INITIATION
Target $41
NORL
Outperform
Alarm.com initiated with an Outperform at Northland
Northland analyst Michael Latimore initiated Alarm.com with an Outperform and a $41 price target.
06/09/17
06/09/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Mindbody (MB) initiated with an Overweight at JPMorgan. 2. Alarm.com (ALRM) initiated with an Outperform at Northland. 3. First Mid-Illinois Bancshares (FMBH) initiated with a Neutral at DA Davidson. 4. Integrated Device (IDTI) initiated with a Buy at Longbow. 5. BWX Technologies (BWXT) initiated with a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
REXX Rex Energy
$2.74

-0.03 (-1.08%)

09/29/16
STFL
09/29/16
UPGRADE
STFL
Hold
Rex Energy upgraded to Hold from Sell at Stifel
09/29/16
STFL
09/29/16
UPGRADE
STFL
Hold
Rex Energy upgraded based on OPEC deal at Stifel
As noted earlier, Stifel upgraded Rex to Hold from Sell. Analyst Michael Scialla upgraded the stock based on an improved oil price outlook after OPEC reportedly agreed to an oil production cut. The analyst says that the production cut may not actually occur, but he believes that other factors, along with positive commentary from OPEC, "appears to be building an oil price floor of $40."
09/29/16
09/29/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. eBay (EBAY) upgraded to Buy from Hold at Deutsche Bank with analyst Ross Sandler saying eBay is likely to outperform Internet peers over the next two years now that its re-platforming is in the latter stages. 2. BlackBerry (BBRY) upgraded to Neutral from Underperform at Macquarie with analyst Gus Papageorgiou saying he expects operations to stabilize and profitability to return next year. 3. Endo (ENDP) upgraded to Outperform from Market Perform at Northland. 4. Rex Energy (REXX) upgraded to Hold from Sell at Stifel with analyst Michael Scialla saying the production cut may not actually occur, but he believes that other factors, along with positive commentary from OPEC, "appears to be building an oil price floor of $40." 5. Incyte (INCY) upgraded to Outperform from Market Perform at Raymond James with analyst Reni Benjamin saying Epacadostat plus pembrolizumab, should ;the results be confirmed in the ongoing Phase III study, could effectively compete with ipilimumab and nivolumab. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GPOR Gulfport Energy
$11.00

-0.23 (-2.05%)

03/30/17
FBCO
03/30/17
NO CHANGE
Target $28
FBCO
Outperform
Gulfport Energy price target lowered to $28 from $33 at Credit Suisse
Credit Suisse analyst Mark Lear lowered his price target for Gulfport Energy to $28 from $33 as lowering long-term gas prices by 25c has a greater effect versus the nearer-term forecast increase. The analyst reiterates an Outperform rating on the shares.
07/20/17
JPMS
07/20/17
DOWNGRADE
Target $17
JPMS
Neutral
Gulfport Energy downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Glick downgraded Gulfport Energy (GPOR) to Neutral saying he's repositioning his ratings ahead of the Q2 reporting season toward names that can perform well in a lower commodity price environment. The analyst calls Parsley Energy (PE) and Diamondback Energy (FANG) his top picks in the small-to-mid cap Exploration & Production space. He lowered his price target for Gulfport shares to $17 from $22.
03/28/17
03/28/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. FIS (FIS) downgraded to Neutral from Buy at Goldman with analyst James Schneider saying he views the current risk/reward as balanced as he believes consensus estimates not reflect margin upside from SunGard. He sees multiple expansion as unlikely following the recent share rally. 2. KVH Industries (KVHI) downgraded to Outperform from Strong Buy at Raymond James with analyst Ric Prentiss saying initial 2017 guidance provided on March 3 was disappointing and believes strategic initiatives will pressure margins in the short-term, but could produce meaningful long-term growth. The analyst thinks 2017 guidance could prove conservative, creating an opportunity to beat reduced expectations. 3. Exelon (EXC) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Stephen Byrd saying shares have outperformed and provide a more balanced risk/reward. 4. Gulfport Energy (GPOR) downgraded to Underweight from Equal Weight at Morgan Stanley. 5. Societe Generale (SCGLY) downgraded to Equal Weight from Overweight at Barclays. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/15/17
WOLF
06/15/17
DOWNGRADE
WOLF
Peer Perform
Gulfport Energy downgraded to Peer Perform from Outperform at Wolfe Research
Wolfe Research transitioned coverage on Gulfport Energy with a Peer Perform from Outperform rating.
PXLW Pixelworks
$4.72

-0.14 (-2.88%)

05/19/17
ROTH
05/19/17
NO CHANGE
Target $6.5
ROTH
Buy
Pixelworks price target raised to $6.50 after ViXS acquisition at Roth Capital
Roth Capital analyst Brian Alger said he believes the true value of Pixelworks' agreement to buy ViXS Systems, which specializes in UHD video processing, is in the scale the additional R&D resources bring. Alger raised his price target on Pixelworks to $6.50, from $5.50 given the upside potential that ViXS brings to the organic business and keeps a Buy rating on the shares.
HTZ Hertz
$14.28

-0.96 (-6.30%)

08/04/17
JPMS
08/04/17
INITIATION
Target $15
JPMS
Neutral
Hertz initiated with a Neutral at JPMorgan
JPMorgan analyst Samik Chatterjee started Hertz with a Neutral rating and $15 price target. The analyst believes greater profit growth is possible but sees higher execution risk.
08/04/17
08/04/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Square (SQ) initiated with a Neutral at Wedbush. 2. Avis Budget (CAR) was initiated with an Overweight at JPMorgan while Hertz (HTZ) was initiated with a Neutral at the firm. 3. IBM (IBM) initiated with a Neutral at Wedbush. 4. Amtech Systems (ASYS) initiated with a Buy at Roth Capital. 5. Franklin Financial Network (FSB) initiated with a Market Perform at Hovde Group. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/31/17
07/31/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Facebook (FB) downgraded to Sell from Hold at Pivotal Research with analyst Brian Wieser saying the shares are not factoring in risks to the company's growth following their "remarkable run" this year. 2. Ulta Beauty (ULTA) downgraded to Perform from Outperform at Oppenheimer with analyst Rupesh Parikh saying softer commentary from L'Oreal on its earnings call, increasing promotional activity from the department store channel, and more difficult year-over-year comparisons "could now signal a potentially more challenging beauty backdrop going forward." 3. Hertz (HTZ) downgraded to Underweight from Equal Weight at Barclays with analyst Brian Johnson saying fundamentals may have bottomed, but the stock is ignoring the challenges ahead in the company's earnings recovery following the nearly 100% rally since June 21. 4. Citi (C) downgraded to Market Perform from Outperform at BMO Capital with analyst James Fotheringham citing valuation and lack of catalysts. 5. Visteon (VC) downgraded to Neutral from Buy at UBS with analyst Colin Langan saying the risk/reward is more balanced with the shares up 60% over the last year. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/31/17
LEHM
07/31/17
DOWNGRADE
Target $9
LEHM
Underweight
Hertz downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Brian Johnson downgraded Hertz Global Holdings to Underweight with an unchanged price target of $9. Fundamentals may have bottomed, but the stock is ignoring the challenges ahead in the company's earnings recovery following the nearly 100% rally since June 21, Johnson tells investors in a research note. He expects a "sharp miss" relative to expectations when Hertz reports Q2 results.
GDDY GoDaddy
$42.45

-0.23 (-0.54%)

03/28/17
LEHM
03/28/17
INITIATION
Target $45
LEHM
Overweight
GoDaddy initiated with an Overweight at Barclays
Barclays analyst Deepak Mathivanan initiated GoDaddy with an Overweight and a $45 price target.
05/16/17
PIPR
05/16/17
NO CHANGE
Target $50
PIPR
Overweight
GoDaddy price target raised to $50 from $46 at Piper Jaffray
Piper Jaffray analyst Samuel Kemp raised his price target for GoDaddy to $50 after analyzing the value of the company's "compounding growth." The analyst is "incrementally more bullish" on GoDaddy's ability to meet and likely exceed its 2018 free cash flow target of $600M. He reiterates an Overweight rating on the shares.
07/20/17
PIPR
07/20/17
NO CHANGE
Target $44
PIPR
Overweight
Piper says Google 'bark-with-no-bite' site builder unlikely to hurt GoDaddy
Piper Jaffray analyst Samuel Kemp noted today's 2% slide in GoDaddy (GDDY) shares, which he attributes to investor attention being drawn to a website builder tool quietly launched by Google (GOOG) a month ago. However, Kemp believes the rudimentary, "bark-with-no-bite" product is unlikely to impact GoDaddy's existing subscriber base and future growth and would be a buyer of GoDaddy shares on the pullback. He keeps an Overweight rating and $44 price target on GoDaddy shares.
06/15/17
PIPR
06/15/17
NO CHANGE
Target $50
PIPR
Overweight
Piper positive on GoDaddy after day with management
After spending a day with management, Piper Jaffray analyst Samuel Kemp calls GoDaddy the "highest quality compounding growth story in our SMid cap coverage." The analyst believes the stock is undervalued and reiterates an Overweight rating on the name with a $50 price target. The company's "increasingly diversified" sources of new customer growth and new GoCentral offering reduce the likelihood of a bookings growth fall-off, Kemp tells investors in a research note.
FOSL Fossil
$11.84

0.64 (5.71%)

03/03/17
WELS
03/03/17
NO CHANGE
WELS
Fossil has 'additional red flags,' says Wells Fargo
Wells Fargo says that Fossil's (FOSL) 10K shows that the company "is generating steep losses in the U.S." Wells adds that Adidas is terminating its partnership with Fossil nine months earlier than expected, while many of Fossil's selling prices are dropping and the sales declines of its Michael Kors (KORS) brand are accelerating. Wells says that the company's U.S. issues could cause it to violate debt covenants. Wells keeps an Underperform rating on the stock.
04/28/17
OTRG
04/28/17
NO CHANGE
OTRG
Fossil's overall sales continue to struggle, says OTR Global
OTR Global's distributor checks indicate Fossil continues to struggle with overal sales during the quarter as slowing demand for smartwatches contributed to general weakness as traditional watch sale declined.
06/20/17
BUCK
06/20/17
UPGRADE
BUCK
Neutral
Fossil upgraded to Neutral from Underperform at Buckingham
Buckingham upgraded Fossil to Neutral saying shares have pulled back below its $10 price target reaching levels not seen since the FY09 recession. The firm's analyst believes Fossil's negative thesis has played out, limiting additional near-term negative catalysts to move the stock lower from here.
06/20/17
06/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. McDonald's (MCD) upgraded to Outperform from Market Perform at Cowen with analyst Andrew Charles saying value and digital are multi-year growth drivers. The firm's proprietary survey data indicates McDonald's value perceptions versus quick service peers has improved since last September when it began to market both the McPick 2 for $5 value platform and discounts only available through the app. 2. Costco (COST) upgraded to Buy from Neutral at Northcoast with analyst Chuck Cerankosky saying Costco is able to combine value merchandising with an upscale product selection in a destination shopping format, is taking market share in fresh food categories, and is shown to be relatively immune to food deflation over the past several quarters. 3. Fossil (FOSL) upgraded to Neutral from Underperform at Buckingham with the firm's analyst saying shares have pulled back below its $10 price target reaching levels not seen since the fiscal 2009 recession. 4. Goodyear Tire (GT) upgraded to Buy from Hold at Jefferies with analyst Ashik Kurian citing "improving volume momentum and strong cash returns." 5. Clovis (CLVS) upgraded to Buy from Neutral at Janney Capital with analyst Debjit Chattopadhyay citing the ARIEL3 data, which he said addressed the PARP differentiation question. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TRUE TrueCar
$19.51

-0.17 (-0.86%)

03/27/17
SBSH
03/27/17
INITIATION
Target $18
SBSH
Buy
TrueCar initiated with a Buy at Citi
Citi analyst Mark Kelley started TrueCar with a Buy rating and $18 price target. The continued shift to used cars and affinity sales should drive upside to estimates, the analyst contends.
03/03/17
RBCM
03/03/17
NO CHANGE
RBCM
Yelp, TrueCar, LendingTree named top Internet small caps at RBC Capital
RBC Capital analyst Mark Mahaney named Yelp (YELP), TrueCar (TRUE), and LendingTree (TREE) as his top small cap Internet stocks. Yelp's sales force productivity issues in Q4 were probably "temporary," and its platform carries "rising strategic value," the analyst stated. TrueCar may have the biggest positive turnaround among small and medium size Internet stocks this year. He thinks that "TrueCar addresses a critical consumer need, has a large addressable market, and presents a differentiated value proposition to both car dealers and consumers." LendingTree's (TREE) total available market is "large and underpenetrated," while its mortgage unit has "strong secular tailwinds," according to Mahaney.
02/17/17
RBCM
02/17/17
NO CHANGE
RBCM
TrueCar reported 'very solid' Q4 results, says RBC Capital
RBC Capital analyst Mark Mahaney says that TrueCar reported "very strong" Q4 results. The analyst continues to be very bullish on the company's fundamentals, and he keeps an Outperform rating on the shares.
02/17/17
CHLM
02/17/17
NO CHANGE
Target $20
CHLM
Buy
TrueCar price target raised to $20 from $14 at Craig-Hallum
Craig-Hallum analyst Steve Dyer raised his price target for TrueCar to $20 from $14 as he continues to see significant value in the shares given Q3 results and the subsequent rise in the stock. The analyst reiterates a Buy rating on the shares.
MXL MaxLinear
$24.69

0.01 (0.04%)

06/07/17
BNCH
06/07/17
NO CHANGE
Target $10
BNCH
Buy
Sigma Designs could become 'prime acquisition target,' says Benchmark
Following Sigma Designs' (SIGM) report of mixed Q1 results, Benchmark analyst Gary Mobley contends investors care about two main things: growing IoT revenue, which is being seen, and an "outright divestiture" of SmartTV assets. If Sigma can shed assets and become a pure play IoT chip/cloud infrastructure company, Mobley believes it could become a "prime acquisition target" for a radio frequency IC company such as Silicon Laboratories (SLAB) or MaxLinear (MXL). If it is not acquired but can raise $100M by selling non-core, non-IoT businesses, Sigma could make additional acquisitions to bolster its IoT focus, said Mobley, who keeps a Buy rating and $10 price target on the stock.
03/30/17
RILY
03/30/17
DOWNGRADE
Target $13
RILY
Neutral
Exar downgraded to Neutral from Buy at B. Riley
B. Riley analyst Craig Ellis downgraded Exar (EXAR) to Neutral saying the takeover by MaxLinear (MXL) at $13 per share matches his price target.
03/30/17
ROTH
03/30/17
NO CHANGE
Target $35
ROTH
Buy
MaxLinear price target raised to $35 from $30 at Roth Capital
Roth Capital analyst Brian Alger raised his price target for MaxLinear (MXL) to $35 from $30 after the company announced it plans to acquire Exar (EXAR) in an all cash tender offering at $13 per share, or roughly a $470M Enterprise Value. Beyond the cost savings, the analyst sees numerous opportunities for sales synergies. He reiterates a Buy rating on MaxLinear's shares.
03/30/17
STFL
03/30/17
NO CHANGE
STFL
MaxLinear deal positive, says Stifel
After MaxLinear (MXL) agreed to buy Exar (EXAR), Stifel analyst Tore Svanberg says that the deal will enable MaxLinear to enter several new vertical markets, while Exar's customer base does not overlap significantly with that of MaxLinear. The analyst expects MaxLinear to obtain significant revenue synergies from the deal and keeps a Buy rating on the stock.
TRIP TripAdvisor
$39.55

-0.01 (-0.03%)

07/19/17
COWN
07/19/17
UPGRADE
COWN
Market Perform
TripAdvisor upgraded to Market Perform from Underperform at Cowen
07/19/17
07/19/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Boeing (BA) upgraded to Neutral from Underperform at BofA/Merrill with analyst Ronald Epstein citing stronger free-cash-flow generatoin and the impact from large share buybacks. 2. Vertex (VRTX) upgraded to Buy from Neutral at Janney Capital, to Outperform from Market Perform at Raymond James and Cowen, and to Overweight from Equal Weight at Barclays. 3. Chipotle (CMG) upgraded to Outperform from Market Perform at Telsey Advisory with analyst Bob Derrington saying yesterday's pullback in shares, combined with management's more aggressive menu innovation plan, provides a buying opportunity. 4. TripAdvisor (TRIP) upgraded to Market Perform from Underperform at Cowen. 5. First Solar (FSLR) upgraded to Buy from Hold at Axiom with analyst Gordon Johnson II saying that his checks suggest the company has delayed its transition to Series 6 technology as it runs its Series 4 production lines longer to accommodate increased demand. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/12/17
WELS
07/12/17
INITIATION
WELS
Market Perform
trivago initiated with a Market Perform at Wells Fargo
Wells Fargo is upbeat on Trivago's (TRVG) execution and business model. But it is cautious on the stock due to what its says is the stock's above peer valuation and increasing competition from TripAdvisor (TRIP).
07/11/17
PIPR
07/11/17
NO CHANGE
PIPR
Overweight
Piper survey shows 'significant increase' in Priceline market share
Piper Jaffray analyst Michael Olson says his firm's survey of 1,000 U.S. consumers increases his confidence in his Overweight ratings on Priceline (PCLN) and Expedia (EXPE). The survey shows a "significant increase" in market share for Priceline brands, "stability" for Expedia brands and a decline in the number of people who either book direct on a hotel website or do not book travel online at all, Olson tells investors in a research note. He reiterates Overweight ratings on both Priceline and Expedia and maintains a Neutral rating on TripAdvisor (TRIP).
PCLN Ticker changed to BKNG
$2,049.00

6.36 (0.31%)

07/28/17
PIPR
07/28/17
NO CHANGE
Target $2150
PIPR
Overweight
Priceline price target raised to $2,150 from $1,900 at Piper Jaffray
Piper Jaffray analyst Michael Olson raised his price target for Priceline shares to $2,150 saying he expects a "solid" quarter when the company reports on August 8. Priceline is well positioned to capture an increasing share of travel bookings in the company's core international markets, Olson tells investors in a pre-earnings research note. He believes 2020 earnings per share of greater than $110 is achievable, if not conservative. Olson reiterates an Overweight rating on the shares.
07/18/17
MSCO
07/18/17
NO CHANGE
Target $2100
MSCO
Priceline price target raised to $2,100 from $1,950 at Morgan Stanley
Morgan Stanley analyst Brian Nowak raised Priceline's price target to $2,100 from $1,950 and increased EBITDA estimates for 2017/18 by 3%/7% to reflect continued US Booking.com strength. The analyst said Comscore analysis indicates Booking.com's US traffic growth remains strong, up 25% year-over-year in Q2, with US online bookings share growing, and larger traffic bases leading to long-term gains in share. Nowak rates Priceline an Overweight
08/01/17
FBCO
08/01/17
NO CHANGE
Target $2150
FBCO
Outperform
Priceline price target raised to $2150 from $2020 at Credit Suisse
Credit Suisse analyst Paul Bieber raised his price target for Priceline to $2150 from $2020 ahead of Q2 results. The analyst reiterates an Outperform rating on the shares.
Z Zillow
$47.93

0.43 (0.91%)

06/22/17
CHLM
06/22/17
INITIATION
Target $58
CHLM
Buy
Zillow assumed with a Buy at Craig-Hallum
Craig-Hallum analyst Bradley Berning assumed coverage of Zillow with a Buy rating and $58 price target, citing its potential to disrupt real estate lead generation.
07/05/17
STFL
07/05/17
NO CHANGE
STFL
Zillow price target raised to $54.50 from $46 at Stifel
Stifel analyst George Askew expects Zillow's Q2 results to exceed expectations. He thinks that the company continued to execute well in Q2 and benefited from volume and pricing leverage as well as expense control. He keeps a Buy rating on the shares.
07/18/17
07/18/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zillow (Z, ZG) initiated with a Sector Weight at KeyBanc. 2. Electronic Arts (EA) and Activision Blizzard (ATVI) were initiated with a Buy at Needham. 3. Infinera (INFN) initiated with a Buy at Craig-Hallum. 4. Baker Hughes (BHGE) reinstated with a Sell at Goldman Sachs. 5. Acadia (ACHC) initiated with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/07/17
DBAB
08/07/17
NO CHANGE
Target $50
DBAB
Hold
Zillow price target raised to $50 from $44 at Deutsche Bank
Deutsche Bank analyst Lloyd Walmsley raised his price target for Zillow to $50 saying he sees "meaningful upside" to 2017 and 2018 revenue estimates as StreetEasy monetization ramps. The analyst, however, keeps a Neutral rating on the shares saying he's more concerned about risk from mortgage co-advertising around the CFPB investigation.
ZG Zillow
$47.74

0.31 (0.65%)

05/05/17
NEED
05/05/17
NO CHANGE
Target $48
NEED
Buy
Zillow price target raised to $48 from $41 at Needham
Needham analyst Kerry Rice raised his price target for Zillow to $48 from $41 after the company reported "strong Q1" revenue and EBITDA upside. The analyst reiterates a Buy rating on the shares.
07/17/17
KEYB
07/17/17
INITIATION
KEYB
Sector Weight
Zillow initiated with a Sector Weight at KeyBanc
OCUL Ocular Therapeutix
$5.95

-0.09 (-1.49%)

07/26/17
HCWC
07/26/17
INITIATION
Target $10
HCWC
Buy
Ocular Therapeutix initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started Ocular Therapeutix with a Buy rating and $10 price target. The analyst believes Dextenza could generate peak sales of $325M in 2031 by targeting the 4M cataract surgeries in the U.S. alone.
07/26/17
07/26/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AMD (AMD) initiated with an Outperform at Baird. 2. Altice USA (ATUS) initiated with a Market Perform at Wells Fargo. 3. Callidus Software (CALD) initiated with a Buy at Jefferies. 4. Jones Lang LaSalle (JLL) initiated with a Neutral at UBS. 5. Ocular Therapeutix (OCUL) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/12/17
CANT
07/12/17
NO CHANGE
Target $21
CANT
Overweight
Ocular Therapeutix price target lowered to $21 from $35 at Cantor
Cantor Fitzgerald analyst Elemer Piros lowered his price target for Ocular Therapeutix to $35 after the company received a Complete Response Letter from the FDA for Dextenza in post-surgical ocular pain. The analyst adjusted his model to reflect a 12-month delayed launch but remains confident that Ocular will be able to resolve the issues. Piros keeps an Overweight rating on the shares.
07/12/17
COWN
07/12/17
NO CHANGE
Target $60
COWN
Outperform
Cowen keeps Outperform rating, $60 target on Ocular Therapeutix
Cowen analyst Ken Cacciatore says that while another Complete Response Letter from the FDA related to the Dextenza manufacturing process is disappointing, the issue could be resolved within the next year. Patient investors will eventually be rewarded for the company's OTX-TP glaucoma opportunity, Cacciatore tells investors in a research note. He keeps an Outperform rating on Ocular with a $60 price target. The stock in morning trading is down 18% to $6.20.
JAZZ Jazz Pharmaceuticals
$152.29

-3.27 (-2.10%)

06/07/17
JPMS
06/07/17
NO CHANGE
JPMS
Overweight
Jazz Pharmaceuticals data beat investor expectations, says JPMorgan
JPMorgan analyst Jessica Fye believes full results from the Phase III JZP-110 narcolepsy and obstructive sleep apnea studies established a "compelling clinical profile" and beat investor expectations. JZP-110 represents a long-term growth driver outside of Xyrem, Fye tells investors in a research note. She believes the current valuation does not fully the double-digit growth she expects Jazz to generate over the next several years. The analyst reiterates an Overweight rating on the shares.
06/07/17
COWN
06/07/17
NO CHANGE
Target $190
COWN
Outperform
Cowen tells investors to be involved now in Jazz Pharmaceuticals
Cowen analyst Ken Cacciatore noted Jazz Pharmaceuticals presented positive Phase lll data on its drug candidate to treat daytime sleepiness and said the results were as good as could be hoped for. Given its efficacy/safety profile, he believes JZP-110 is "best-in-class" and likely a $750M product and recommends investors get involved now. Cacciatore reiterated his Outperform rating and $190 price target on Jazz Pharmaceuticals shares.
08/03/17
BMOC
08/03/17
NO CHANGE
BMOC
Outperform
Vyxeos label an 'upside suprise' for Jazz, says BMO Capital
BMO Capital analyst Gary Nachman said the FDA approval of Jazz Pharmaceuticals' Vyxeos for "poor-prognosis" AML patients came "on the earlier side of expectations" and with the "upside surprise" that there are no age restrictions in the label indication. The analyst, who said he is still bullish on the prospects for Vyxeos, keeps an Outperform rating on Jazz shares.
08/08/17
COWN
08/08/17
NO CHANGE
Target $190
COWN
Outperform
Jazz Pharmaceuticals assets undervalued, says Cowen
Cowen analyst Ken Cacciatore said Jazz Pharmaceuticals provided input from clinical consultants and its own commentary on Vyxeos, which increased conviction in the drug. Cacciatore, who believes the totality of its assets are undervalued, reiterated his Outperform rating and $190 price target on Jazz shares.
DIS Disney
$106.98

0.63 (0.59%)

08/04/17
JEFF
08/04/17
NO CHANGE
Target $78
JEFF
Buy
Activision Blizzard building Disney-type media business, says Jefferies
Jefferies analyst Timothy O'Shea raised his price target for Activision Blizzard (ATVI) to $78 from $68 while listing five reasons to buy the stock in a post-earnings research note. The company generated $1B of in-game spending in Q2, which is a "meaningful driver" of margin expansion, O'Shea writes. He expects Destiny 2 and Call of Duty WW2 to drive strong second half of 2017 results. Activision is building a Disney-type media business for the 21st Century, argues O'Shea. He keeps a Buy rating on the shares.
06/23/17
BOFA
06/23/17
NO CHANGE
BOFA
Buy
Disney removed from US 1 list at BofA/Merrill (pre-open)
BofA/Merrill removed Disney from its US 1 list before the open. The firm keeps a Buy rating on Disney shares.
06/23/17
BOFA
06/23/17
NO CHANGE
Target $125
BOFA
Buy
Disney removed from US 1 List at BofA/Merrill
BofA/Merrill analyst Jessica Reif Cohen removed Disney from the US 1 List and lowered Q2 EBIT estimate to down 10% from up 2% to reflect reduced Consumer Products growth, increased Cable Networks and Studio Entertainment declines, , lower Theme Parks operating income, and softer Broadcasting contribution. The analyst's Q3 earnings estimate goes to $1.53 from $1.75, FY17 to $5.91 from$6.15, and FY18 to $6.70 from $7.16, and her price target goes to $125 from $134. Despite the changes, Cohen believes Disney offers best in class assets with above average growth and maintains a Buy rating.
07/18/17
RBCM
07/18/17
NO CHANGE
RBCM
Disney should be owned into Q3 results, says RBC Capital
RBC Capital analyst Steven Cahall recommends owning Disney stock into the company's Q3 results. The analyst says that the company's Q3 results "may be coming down." However, he remains upbeat on its fiscal 2018 outlook, partly due to his belief that its Parks results will beat expectations.
MNST Monster Beverage
$52.63

-0.24 (-0.45%)

06/20/17
JEFF
06/20/17
NO CHANGE
Target $63
JEFF
Buy
Monster Beverage looks attractively valued, says Jefferies
Jefferies analyst Kevin Grundy says Monster Beverage remains a top pick following "upbeat commentary" at the company's shareholder meeting. Positives included "bullish" commentary on international growth and margin, an "encouraging" U.S. outlook, and long-term drivers to grow penetration, Grundy tells investors in a research note. He views the shares as attractively valued and reiterates a Buy rating on Monster with a $63 price target.
06/01/17
JEFF
06/01/17
NO CHANGE
JEFF
Jefferies reiterates Monster, Newell as top picks
Jefferies analyst Kevin Grundy reiterates Monster Beverage (MNST) and Newell Brands (NWL) as top picks while addressing "common investor pushbacks." For Monster, the analyst believes improving U.S. results, continued strong international growth and M&A optionality should lead to continued outperformance. For Newell, the analyst sees an attractive valuation and improving organic sales growth. He reiterates Buy ratings on both names.
07/19/17
JEFF
07/19/17
NO CHANGE
JEFF
Jefferies lays out stocks 'overly discounting' Amazon risk
Amazon.com's (AMZN) planned purchase of Whole Foods Market (WFM) has further widened the valuation spread between consumer stocks the market views as resistant to the Aamzon threat and those viewed as vulnerable, Jefferies analysts including Andy Barish and Daniel Binder tells investors in a research note. They believe this dynamic has created opportunities. Specifically, the analysts feel shares of Wal-Mart (WMT), Hain Celestial (HAIN), Foot Locker (FL) and Advance Auto Parts (AAP) are "overly discounting" potential risk from Amazon. Jefferies also believes Casey's General Stores (CASY), Lamb Weston (LW), Murphy USA (MUSA), Monster Beverage (MNST), Starbucks (SBUX) and Ulta Beauty (ULTA) are "well insulated" from Amazon disruption.
06/20/17
UBSW
06/20/17
NO CHANGE
Target $59
UBSW
Buy
Monster Beverage growth runway remains attractive, says UBS
UBS analyst Stephen Powers said the Monster Beverage shareholder meeting was highlighted by an upbeat management tone. The team sees its growth coming from international distribution and its top-line growth driven by select innovation, he noted. Powers reiterated his Buy rating and raised his price target to $59 from $57 on Monster Beverage shares.
NUAN Nuance
$17.02

0.02 (0.12%)

06/12/17
DBAB
06/12/17
NO CHANGE
Target $25
DBAB
Buy
Nuance's new products double addressable market, says Deutsche Bank
Deutsche Bank analyst Nandan Amladi believes Nuance's new healthcare products "significantly expand" the company's market opportunity. New software that uses clinical language understanding techniques on transcribed notes to ensure that the documentation is complete doubles Nuance's market opportunity to about $5B, Amladi tells investors in a research note. He reiterates a Buy rating on the shares with a $25 price target.
01/06/17
LEHM
01/06/17
UPGRADE
Target $19
LEHM
Overweight
Nuance upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Saket Kalia upgraded Nuance Communications to Overweight calling the company a turnaround pick for 2017. The analyst sees limited downside from current share levels and sees 2017 as the revenue growth. Kalia raised his price target for the shares to $19 from $17.
06/29/17
CHLM
06/29/17
NO CHANGE
Target $24
CHLM
Buy
Nuance growth engine in healthcare not affected by hack, says Craig-Hallum
Craig-Hallum analyst Jeff Van Rhee noted that Nuance has been impacted by the "NotPetya" ransomware attack, though "very importantly" the hack doesn't appear to have affected Dragon Cloud services, which he identifies as the company's critical growth engine within healthcare. In fact, the opening of this platform for legacy transcription customers who have been impacted by the hack may accelerate their migration to Dragon Cloud, Van Rhee tells investors. While potential lost revenue from legacy transcription is meaningful, the analyst sees reputational risk as the larger issue and views it as "noteworthy" that the Dragon product has remained online. He keeps a Buy rating and $24 price target on Nuance shares.
11/18/16
RAJA
11/18/16
UPGRADE
RAJA
Strong Buy
Nuance upgraded to Strong Buy from Outperform at Raymond James
NFLX Netflix
$178.36

-2.97 (-1.64%)

07/26/17
BTIG
07/26/17
NO CHANGE
BTIG
Netflix price target raised to $225 from $170 at BTIG
BTIG analyst Richard Greenfield increased his price target on Netflix as he raised his 2017 subscriber estimate for the company by 2.4M and says that the company is threatening conventional TV broadcasters. The analyst says he is surprised by the acceleration of U.S. subscriber growth ,and he keeps a Buy rating on the shares.
07/18/17
07/18/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Netflix (NFLX) upgraded to Buy from Neutral at Rosenblatt with analyst Alan Gould saying the report was "just too good" not to reexamine his rating. The analyst increased his price target to $200 from $155. 2. Chipotle (CMG) upgraded to Buy from Hold at Maxim with analyst Stephen Anderson saying he believes that the introduction of queso dip will be an important catalyst in 2018 and now thinks the recent pullback in shares provide an opportunity to participate in the recovery at Chipotle. Anderson raised his 2018 earnings per share estimate to factor in a phased-in introduction of queso nationwide and increased his price target on Chipotle shares to $460 from $440. 3. O'Reilly Automotive (ORLY) upgraded to Buy from Neutral at Northcoast with analyst Nicholas Mitchell saying shares are down over 40% in the past year and believes the slowdown in same-store-sales to start the year was a result of lackluster consumer demand and not a dramatic shift to ecommerce. 4. Fifth Street Finance (FSC) upgraded to Buy from Neutral at National Securities and to Buy from Hold at Deutsche Bank. 5. SeaWorld (SEAS) upgraded to Neutral from Sell at Goldman Sachs with analyst Christopher Prykull saying that while concerns remain, the risk/reward is more balanced at current share levels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/27/17
MKMP
07/27/17
NO CHANGE
MKMP
Buy
Netflix earnings of $30 possible over time, price target to $230 at MKM Partners
MKM Partners analyst Rob Sanderson raised Netflix's price target to $230 from $195 and said he continues to believe the global opportunity is very large. The analyst is looking for $12 of earnings power in 2021 and thinks $30 of earnings power is possible over time when modeling 90M US and 300M international subscribers, modest ARPU increases and a $24B content budget. Sanderson rates Netflix a Buy.
08/08/17
PIPR
08/08/17
NO CHANGE
Target $215
PIPR
Overweight
Netflix price target raised to $215 from $198 at Piper Jaffray
Piper Jaffray analyst Michael Olson raised his price target for Netflix shares to $215 to reflect increased international subscriber estimates. The streaming service closed yesterday up $1.06 to $181.33. By 2020, the analyst expects Netflix will reach 64M domestic subscribers or 50% U.S. household penetration. His analysis suggests that Netflix can reach 100M international subscribers by 2020, with "zero or very minimal penetration in lower income international markets." Olson increased his international subscriber estimate for 2020 to 100M and believes "this could still be conservative." The analyst keeps an Overweight rating on Netflix.

TODAY'S FREE FLY STORIES

NWN

Northwest Natural Gas

$62.63

0.075 (0.12%)

, PCG

PG&E

$42.98

2.44 (6.02%)

18:17
06/22/18
06/22
18:17
06/22/18
18:17
Hot Stocks
Northwest Natural to sell Gill Ranch Storage to SENSA Holdings »

NW Natural (NWN)…

NWN

Northwest Natural Gas

$62.63

0.075 (0.12%)

PCG

PG&E

$42.98

2.44 (6.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

ORLY

O'Reilly Automotive

$285.90

-1.18 (-0.41%)

18:03
06/22/18
06/22
18:03
06/22/18
18:03
Hot Stocks
O'Reilly Automotive's O'Reilly sells 19,250 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJI

South Jersey Industries

$33.15

0.02 (0.06%)

17:46
06/22/18
06/22
17:46
06/22/18
17:46
Hot Stocks
South Jersey Industries announces approval of Elizabethtown Gas purchase »

South Jersey Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAAS

AquaVenture

$15.36

0.12 (0.79%)

17:27
06/22/18
06/22
17:27
06/22/18
17:27
Hot Stocks
AquaVenture extends long-stop date for Ghana plant acquisition to September 30 »

AquaVenture announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

17:22
06/22/18
06/22
17:22
06/22/18
17:22
Periodicals
Nissan chooses Thailand for hybrid's first export market, Nikkei reports »

Nissan has planned to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TROV

Trovagene

$0.81

-0.0068 (-0.83%)

17:22
06/22/18
06/22
17:22
06/22/18
17:22
Hot Stocks
Trovagene CEO William Welch resigns, Dr. Thomas Adams named interim CEO »

Trovagene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$3.26

0.005 (0.15%)

17:19
06/22/18
06/22
17:19
06/22/18
17:19
Syndicate
Breaking Syndicate news story on CEL-SCI »

CEL-SCI files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACM

Aecom

$33.49

-0.15 (-0.45%)

17:19
06/22/18
06/22
17:19
06/22/18
17:19
Hot Stocks
Aecom to compete for $148.5M U.S. Army contract »

AECOM-Baker JV, Bryan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$298.95

-1.39 (-0.46%)

17:17
06/22/18
06/22
17:17
06/22/18
17:17
Hot Stocks
Lockheed Martin awarded $175.3M U.S. Navy contract modification »

Lockheed Martin is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

LMT

Lockheed Martin

$298.95

-1.39 (-0.46%)

17:16
06/22/18
06/22
17:16
06/22/18
17:16
Hot Stocks
Lockheed Martin awarded $1.12B U.S. Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

XLE

Energy Select Sector SPDR

$75.21

1.59 (2.16%)

, XLU

Utilities SPDR

$50.75

0.36 (0.71%)

17:14
06/22/18
06/22
17:14
06/22/18
17:14
General news
Week ending ETF Scorecard: Utilities and Real Estate advance, Industrials slump »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$75.21

1.59 (2.16%)

XLU

Utilities SPDR

$50.75

0.36 (0.71%)

IYR

DJ US Real Estate Index Fund

$80.69

0.56 (0.70%)

XLP

Consumer Staples Sector SPDR

$51.62

0.42 (0.82%)

XLY

Consumer Discretionary Sector SPDR

$111.34

-0.15 (-0.13%)

XLB

S&P Select Materials SPDR

$58.49

0.79 (1.37%)

XLF

Financial Select Sector

$27.07

-0.145 (-0.53%)

XLV

Health Care Select Sector SPDR

$84.91

0.35 (0.41%)

XLK

Technology Select Sector SPDR

$70.78

-0.24 (-0.34%)

XLI

Industrial Select Sector SPDR

$72.59

0.22 (0.30%)

GLD

SPDR Gold Trust

$120.33

0.27 (0.22%)

SLV

iShares Silver Trust

$15.49

0.135 (0.88%)

USO

United States Oil Fund

$14.02

0.71 (5.33%)

UNG

United States Natural Gas Fund

$23.87

-0.24 (-1.00%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.91

-0.015 (-0.02%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$113.99

0.105 (0.09%)

TLT

iShares 20+ Year Treasury Bond Fund

$120.57

0.06 (0.05%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.11

0.03 (0.03%)

SHY

iShares 1-3 Year Treasury Bond

$83.30

0.005 (0.01%)

IWD

iShares Russell 1000 Value

$122.51

0.56 (0.46%)

IWF

iShares Russell 1000 Growth

$146.24

-0.2 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFNX

Pfenex

$5.43

0.14 (2.65%)

17:01
06/22/18
06/22
17:01
06/22/18
17:01
Hot Stocks
Pfenex set to join Russell 2000 Index »

Pfenex announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXE

Bellatrix Exploration

$1.00

-0.0101 (-1.00%)

17:01
06/22/18
06/22
17:01
06/22/18
17:01
Syndicate
Breaking Syndicate news story on Bellatrix Exploration »

Bellatrix Exploration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGI

Logitech

$44.24

0.25 (0.57%)

16:56
06/22/18
06/22
16:56
06/22/18
16:56
Initiation
Logitech initiated  »

Logitech initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$30.35

0.925 (3.14%)

16:51
06/22/18
06/22
16:51
06/22/18
16:51
Hot Stocks
Breaking Hot Stocks news story on PagSeguro Digital »

Point72 Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

APLS

Apellis

$21.75

-0.2 (-0.91%)

16:50
06/22/18
06/22
16:50
06/22/18
16:50
Conference/Events
Apellis to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$274.75

0.47 (0.17%)

16:50
06/22/18
06/22
16:50
06/22/18
16:50
Periodicals
SEC investigates whether companies rounded up earnings, WSJ reports »

The U.S. Securites and…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$274.75

0.47 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THRM

Gentherm

$38.20

-0.75 (-1.93%)

16:45
06/22/18
06/22
16:45
06/22/18
16:45
Conference/Events
Gentherm to hold a strategic update »

Strategic Update for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGTX

MeiraGTx

$11.86

-0.97 (-7.56%)

16:43
06/22/18
06/22
16:43
06/22/18
16:43
Hot Stocks
Breaking Hot Stocks news story on MeiraGTx »

Perceptive Advisors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$86.80

0.51 (0.59%)

16:39
06/22/18
06/22
16:39
06/22/18
16:39
Conference/Events
Medtronic to hold an analyst and investor briefing »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

FOXA

21st Century Fox

$48.59

0.25 (0.52%)

, FOX

21st Century Fox

$48.28

0.31 (0.65%)

16:35
06/22/18
06/22
16:35
06/22/18
16:35
Hot Stocks
21st Century Fox extends CFO John Nallen's employment contract to 2021 »

On June 22, 21st Century…

FOXA

21st Century Fox

$48.59

0.25 (0.52%)

FOX

21st Century Fox

$48.28

0.31 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENC

Fennec

$10.97

0.5 (4.78%)

16:34
06/22/18
06/22
16:34
06/22/18
16:34
Hot Stocks
Breaking Hot Stocks news story on Fennec »

Opaleye Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBBP

Strongbridge Biopharma

$6.20

-0.15 (-2.36%)

16:33
06/22/18
06/22
16:33
06/22/18
16:33
Hot Stocks
Breaking Hot Stocks news story on Strongbridge Biopharma »

Opaleye Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 26

    Jun

16:30
06/22/18
06/22
16:30
06/22/18
16:30
Options
Preliminary option volume of 16.8M today »

Preliminary option volume…

COOL

PolarityTE

$38.91

-0.09 (-0.23%)

16:28
06/22/18
06/22
16:28
06/22/18
16:28
Conference/Events
PolarityTE to hold a meeting »

Management hosts a Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.